Pharmacological blockade of kinin B1R could prove to be a valuable new tool in the control of neurogenic hypertension, particularly in patients with refractory hypertension by decreasing circulating AVP, downregulating the orexin A system, and decreasing neuroinflammation. This evidence concerns the gene AVP and hypertensive disorder.